<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01040715</url>
  </required_header>
  <id_info>
    <org_study_id>TNF-K-003</org_study_id>
    <secondary_id>2009-012041-35</secondary_id>
    <nct_id>NCT01040715</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of TNFa Kinoid in Rheumatoid Arthritis With Secondary Resistance to TNFa Antagonists</brief_title>
  <official_title>A Phase II, Randomized, Double-blind, Controlled Study to Evaluate the Immune Responses, Safety and Clinical Efficacy of Three Doses of Neovacs' TNF-Kinoid in Adult Patients With Rheumatoid Arthritis Who Have Relapsed Despite Anti-TNFα Biological Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovacs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neovacs</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to demonstrate that active immunization with anti-TNFα kinoid
      (TNF-K) is able to induce polyclonal anti-TNFα antibodies in RA patients who were previously
      treated with anti-TNFα mAb but have lost susceptibility to therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with at least a 3-fold increase in antibody response to TNFa vs baseline at day 38</measure>
    <time_frame>Day 38</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a decrease of at least 1.2 in DAS28 at month 3 vs baseline</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>TNFa Kinoid dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TNFa Kinoid dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TNFa Kinoid dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TNFa Kinoid</intervention_name>
    <description>TNFa kinoid</description>
    <arm_group_label>TNFa Kinoid dose 1</arm_group_label>
    <arm_group_label>TNFa Kinoid dose 2</arm_group_label>
    <arm_group_label>TNFa Kinoid dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TNF kinoid</intervention_name>
    <description>IM administration 2 or 3 injections within 28 days</description>
    <arm_group_label>TNFa Kinoid dose 1</arm_group_label>
    <arm_group_label>TNFa Kinoid dose 2</arm_group_label>
    <arm_group_label>TNFa Kinoid dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA according to the revised 1987 criteria of the American College of
             Rheumatology (ACR) (Arnett 1988) since at least six months prior to first study
             product administration.

          -  Male or female between 18 and 70 years of age at the time of the first immunization

          -  Active RA disease as evidenced by a Disease Activity Score 28 (DAS 28) ≥ 3.2.

          -  Current or past treatment with an anti-TNF antagonist (infliximab,
             adalimumab,etanercept, certolizumab, golimumab).

          -  A wash-out period before the first administration of the study product of at least ten
             weeks since the last administration of certolizumab or golimumab; at least eigth weeks
             since the last administration of infliximab; at least four weeks since the last
             administration of adalimumab or etanercept

          -  History of positive response defined as an ACR20 or DAS 28 decrease ≥ 1.2 or by the
             investigator opinion with previous TNFα antagonist treatment.

          -  Secondary treatment failure to maximum one previous TNFα antagonist treatment as
             defined by:

          -  Investigator opinion. OR

          -  DAS28 increase ≥ 0.6 during the last six months. OR

          -  Decrease in European League Against Rheumatoid (EULAR) score.

          -  Written informed consent .

        Exclusion Criteria:

          -  Treatment with non-biological DMARDs within four weeks prior to first study product
             administration. MTX is allowed provided it is administered at as table dosage &lt; ou =
             20 mg/week since at least 4 weeks.

          -  Treatment with any rheumatoid arthritis biological therapy other than TNFα antagonists
             at any time prior to first study product administration.

          -  Administration of high doses of intra-articular corticosteroids for the treatment of
             an acute mono-arthritis (eg knee) within 3 months prior to first study product
             administration. High dose of corticosteroids is defined as &gt; 50 mg triamcinolone or
             equivalent.

          -  History of documented severe bacterial infection within 28 days prior to first
             immunization

          -  History of primary resistance or intolerance to any TNFα antagonist.

          -  History of or current congestive heart failure, controlled or not.

          -  Corticosteroids (prednisone or equivalent, &lt; ou = 10 mg per day) are allowed if they
             are administered at stable dosage since at lesat 4 weeks prior to the first
             immunization. Inhaled and topical steroids are allowed.

          -  Known history of tuberculosis (TB).

          -  Suspicion of TB at chest X-rays at screening or within three months prior to first
             administration of study product.

          -  Suspicion of latent or active tuberculosis as defined by :

          -  Positive Mantoux/Purified Protein Derivative (PPD)test (&gt; ou = 5mm induration measured
             48 to 72 hours after intradermal injection of tuberculin) at screening or within 30
             days prior to first administration of study product.

          -  and/or positive interferon-γ (IFN γ) TB diagnostic test (as measured by the ELISpot
             method) at screening or within three months prior to first administration of study
             product.

          -  Positive for HIV, HCV or HBV including HBsAg and anti-HBc antibodies.

          -  Use of any investigational or non-registered product (drug or vaccine).

          -  Administration of any live vaccine within three months prior to study entry

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Durez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires St Luc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro especializado en Investigaciones Medicas (CEIM)</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sirio Libanes</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Cordoba</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Reumatologicas</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Privado de Reumatología</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiteit ZiekenHuis Katholiek Universiteit Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaires Cliniques St. Luc (Mont-Godinne)</name>
      <address>
        <city>Mont-Godinne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic and Consulting Center SV</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Multiprofile Transport Hospital &quot;Tzar Boris III&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital for Active Treatment &quot;Sveti Ivan Rilski&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBAL University Stara Zagora</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Chaika&quot; Ltd</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Sociedad Médica del Aparato Locomotor SA&quot;</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Reumatológicos- Estudios Clínicos Limitada&quot;</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Karlovac</name>
      <address>
        <city>Karlovac</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thalassotherapia</name>
      <address>
        <city>Opatija</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KBC Split</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital &quot;Sveti Duh&quot;</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Sisters of Mercy</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre, Université Paris-Sud 11, INSERM U802</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Xavier Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital La Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg-Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Dr. Constantin Opris&quot; Emergency County Hospital Baia Mare</name>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Dr. I Cantacuzino&quot; Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ianuli Med Consult SRL</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Clinical Hospital Iasi</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Romania</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2009</study_first_submitted>
  <study_first_submitted_qc>December 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2009</study_first_posted>
  <last_update_submitted>September 17, 2014</last_update_submitted>
  <last_update_submitted_qc>September 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>anti-drug antibodies</keyword>
  <keyword>Rheumatoid arthritis with secondary loss of efficacy to anti-TNFa antagonists and anti-drug antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

